Need Help?
Contact Us

Express™ SD

Renal and Biliary Premounted Stent System

The Express SD Stent couples excellent compression resistance with lower stent foreshortening and recoil. Only Express SD has the ideal balance of strength and precision for acute success, every time.

Key Resources

Express SD Stent System Directions for Use Patient Guide - Understanding Renal Artery Disease Indications, Safety, and Warnings

Explore

Product Details

Best-in-Class Compression Resistance

Express™ SD Renal and Biliary Premounted Stent System Best-in-Class Compression Resistance Express™ SD Renal and Biliary Premounted Stent System Best-in-Class Compression Resistance

Minimal Foreshortening

Express™ SD Renal and Biliary Premounted Stent System Foreshortening bench test results Express™ SD Renal and Biliary Premounted Stent System Foreshortening bench test results

Very Low Recoil

Express™ SD Renal and Biliary Premounted Stent System shows Very Low Recoil in Bench Tests Express™ SD Renal and Biliary Premounted Stent System shows Very Low Recoil in Bench Tests

Express SD features a patented Tandem Architecture™ Stent Design

  • Macro™ Elements and additional proximal connectors engineered to provide strength, especially in ostial lesions
  • Micro™ Elements designed to provide flexibility during stent placement

Express SD features a patented Tandem Architecture™ Stent Design Express SD features a patented Tandem Architecture™ Stent Design

Clinical Information

RENAISSANCE Clinical Trial

Overview The RENAISSANCE Trial was a prospective, multi-center, single arm study designed to evaluate the Express SD Renal Premounted Stent System in the treatment of atherosclerotic lesions in the aortorenal ostium.

The primary objective was to demonstrate superiority of the duplex triggered, angiographically-confirmed binary restenosis rate at 9-months over the 40% pre-specified Objective Performance Criterion (OPC) representative of PTRA. 

Trial Design The RENAISSANCE Trial enrolled 100 patients (117 lesions) with de novo or restenotic ostial atherosclerotic lesions ≤15mm long in vessels between 4.0 and 7.0mm diameter with diameter stenosis ≥70%. 

Outcomes Primary Endpoint: 21.3% binary in-stent restenosis rate at 9-months, defined as the proportion of target lesions with ≥50% diameter stenosis based on angiographic core lab assessment.

RENAISSANCE Clinical Trial 5-Year Data RENAISSANCE Clinical Trial 5-Year Data RENAISSANCE Clinical Trial Results RENAISSANCE Clinical Trial Results

Tools & Resources

See More
Top